Generative AI (GenAI) is increasingly being integrated into the Medical Instruments industry, with 50% of U.S. healthcare leaders reporting its use in 2025, according to a McKinsey survey. Over 80% of those surveyed have initiated GenAI applications, focusing on generating synthetic medical images, simulating diseases, and accelerating drug development processes. The FDA’s recent discussion paper highlights both the potential benefits and risks of GenAI-enabled medical devices.
The global AI in healthcare market is projected to grow at a CAGR of 43.9% from 2026 to 2034, with companies like Veracyte, Globus Medical, and UFP Technologies positioned to capitalize on this trend. Furthermore, the industry has seen substantial M&A activity, with $36.5 billion in deals reported in the first half of 2026, indicating ongoing consolidation aimed at innovation and market expansion.
Despite its growth prospects, the Medical Instruments industry has underperformed compared to the S&P 500, with a decline of 2.5% over the past year, while the S&P 500 rose 19%. Currently, the industry trades at a forward P/E of 25.97x, compared to 21.30x for the broader medical sector.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
